JXR (01951) Southern Headquarters set up a "one yard, two centers" to serve the Greater Bay Area and radiate Southeast Asia from Shenzhen.

On March 23, China's leading assisted reproduction group JXR (01951) officially announced the establishment of its southern headquarters in Shenzhen. The southern headquarters will rely on the layout of a "hospital and two centers" with Shenzhen Zhongshan Maternity and Child Health Hospital, Hong Kong Gratitude Medical Center, and Jin Xin Medical Technology Innovation Center as the dual wings, continuously introducing medical resources from Southeast Asia and Europe and America, and building JXR into a strategic hub for the Greater Bay Area and international market. "The establishment of JXR's southern headquarters in Shenzhen is not only a strategic choice for the company to seize the opportunities of the Greater Bay Area development, but also a commitment to contribute to the construction of a high-quality life circle that is livable, suitable for business, and suitable for leisure in the Greater Bay Area. In the future, JXR will strengthen resource integration and regional coordination, further enhancing the integrated reproductive assistance and women's full lifecycle service capabilities with its headquarters in Chengdu and the southern headquarters as the core," said Lu Rong, co-CEO of JXR. In the face of the new population situation, assisted reproduction is experiencing a period of policy opportunity. Currently, China is in a critical period of adjusting its population structure. According to a white paper on the development status and future trends of China's assisted reproduction industry released by the globally renowned consulting firm Frost & Sullivan on March 21, by 2025, China's infertility rate has reached 18%, with over 60 million infertile couples, showing a trend of aging and complexity. Against this background, the country and society are continuously improving the fertility support policy system, and assisted reproductive technology is gradually transitioning from "supplementary medical services" to becoming an "important part of the fertility support system", becoming an important support for building a fertility-friendly society. As a leading enterprise in the domestic assisted reproduction field, JXR has been deeply involved in the industry for 25 years, completing approximately 300,000 assisted reproductive cycles, ranking at the forefront of the country in core indicators such as cycle number and success rate. To help build a fertility-friendly society, JXR can contribute its own efforts. Taking advantage of the opportunity of the relocation of Shenzhen Zhongshan Maternity and Child Health Hospital to the new campus, JXR has formally established its strategic position for the southern headquarters. The new campus, located on Caitian Road in Futian District, Shenzhen, has four times the area of use and is the largest assisted reproduction medical institution in the Greater Bay Area. JXR's relevant person in charge stated that with the new campus as the core, the southern headquarters will collaborate with the services and research advantages of Hong Kong Gratitude Medical Center and Jin Xin Medical Technology Innovation Center, introducing leading industry technology, academic, and management resources from Southeast Asia and Europe and America, targeting the Greater Bay Area, radiating to Southeast Asia and the international market. Currently, JXR is also continuously strengthening talent development to build a talent foundation. After the operation of the new campus of Shenzhen Zhongshan Maternity and Child Health Hospital, many well-known industry experts and doctors have been introduced, such as Li Baoxing, who is known as a "famous doctor in Lingnan" and has previously served as the deputy director of the Urology Department at Shenzhen University. "AI + assisted reproduction" JXR further strengthens technology-driven development The white paper on the development status and future trends of China's assisted reproduction industry until 2026 shows that from 2020 to 2030, with the increase in the proportion of elderly infertility and the improvement in treatment penetration, the Chinese assisted reproduction market is in a stage of demand release, with the market size growing from 23.5 billion yuan to 63 billion yuan. With the improvement in the macro environment and the release of delayed demand, it is expected that 2026-2027 will be a key turning point for the Chinese assisted reproduction industry to transition from the adjustment period to the recovery period, with the industry gradually warming up. Mao Hua, senior partner and director of Sullivan, said that in the future, the assisted reproduction industry will continue to develop under the promotion of technological innovation, digital application, and optimization of service models, and leading organizations in the industry will continuously improve the treatment success rate and patient experience by promoting key technological breakthroughs and clinical practice upgrades. The establishment of the southern headquarters of Jin Xin will further promote the release of JXR's research and technology. According to Wang Weipeng, CEO of Jin Xin Technology, JXR has launched the assisted reproduction AI intelligent body operation system ahead of the industry and landed on the largest assisted reproduction platform Morula in Indonesia. It is reported that JXR continues to increase research investment, promote the application of cutting-edge technologies such as AI embryo assessment, temporal image analysis, and in vitro maturation of immature oocytes for test-tube baby technology in clinics, taking the lead in exploring the path of "AI + assisted reproduction" and has already achieved several clinical application results. Mao Hua believes that against the backdrop of changes in population structure, improvements in fertility support policies, and continuous progress in assisted reproduction technology, China's assisted reproduction industry is still in a stage of long-term development. Based on clinical technology, service capabilities, and international layout dimensions, JXR has formed a relatively complete competitive advantage system, establishing its market position as a leading institution in the Chinese assisted reproduction industry. After the establishment of the southern headquarters, relying on a cross-regional operational network and a scale business foundation, JXR has built a "threefold support" of "technical depth, service breadth, and international height".